Research - News
Young cancer survivors are at higher risk of developing subsequent HPV-related cancers than the general population, but less likely to receive the HPV vaccine. Findings from the first clinical trial of its kind support making HPV vaccination a routine part of oncologic care for all young cancer survivors, researchers say.
Preclinical experiments show how to identify non-responding tumors and improve their response to immunotherapy, using two investigational new drugs that are permitted for human use. Physicians could immediately start investigational research in patients to test the effectiveness of this personalized approach.